[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urology":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,47,80,102,114,147,176,213,241],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":43,"locationsCount":46},"100054328","pelvic-floor-muscle-training-and-dynamic-neuromuscular-stabilization-exercises-in-pediatric-patients-100054328",false,"NCT07267364","Pelvic Floor Muscle Training and Dynamic Neuromuscular Stabilization Exercises in Pediatric Patients","Effects of Adding Dynamic Neuromuscular Stabilization to Pelvic Floor Muscle Training on Voiding Dysfunction in Children: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Having been diagnosed with voiding dysfunction according to ICCS diagnostic criteria in a urology outpatient clinic,\n* Being 5-18 years old,\n* The child and their parent\u002Fguardian agree to participate in the study voluntarily and provide signed consent.\n\nExclusion Criteria:\n\n* Organic pathologies such as urethral obstruction, ectopic ureter, spinal dysraphism, and diabetes\n* Diagnosis of VUR or neurogenic bladder\n* Cognitive and mental impairment\n* Having spina bifida\n* Being under 5 years of age\n* Receiving treatment such as PTC training or electrical stimulation",true,"ALL","5 Years","18 Years",{"count":21,"type":22},48,"ESTIMATED","INTERVENTIONAL",[25],"NA","Dysfunctional voiding (DY) is one of the most common conditions in children. Various treatments are available. Participants will be randomly assigned to either PFMT (Group I) or PFMT+DNS (Group II). PFMT is the gold standard and routinely administered in hospitals for children diagnosed with dysfunctional voiding who are referred by a urologist. The PFMT group serves as the control group, and treatment will be scheduled for a total of 10 weeks, three days a week. During PFMT, children receive instruction about the pelvic floor using video visuals and increase awareness of their pelvic floor muscles. They are then instructed on how to contract and relax their muscles to control urination. DNS training is an exercise model that begins with spinal stabilization and addresses muscle synergies. Patients included in the study will be evaluated twice, at the beginning and at the end of the treatment: Voiding Disorders Symptom Score (VODS), Pediatric Quality of Life Inventory 4.0 (PedsQL 4.0), Pediatric Incontinence Questionnaire (PIN-Q), Bladder Bowel Dysfunction Scale (BDS), Bristol gaita scale, and Children's Body Image Scale.",[28,29],"Urology","Pediatric Disorder",[31,32,33,34],"Voiding dysfunction","pelvic floor muscle training","neuromuscular stabilization","quality of life","RECRUITING","2026-07-10",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":39},"2025-11-11",{"date":36,"type":22},{"name":44,"class":45},"Necmettin Erbakan University","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":46},"100054130","rutiss-diary-and-rutiss-65-study-100054130","NCT07698041","RUTISS-Diary and RUTISS-65 Study","Developing and Validating Two New Patient-Reported Outcome Measures of Recurrent Urinary Tract Infection Symptoms: A Symptoms Diary and Adapted Measure for Older Adults","Inclusion for RUTISS-Diary:\n\n* Participants must be 18 years and older\n* All participants must have native\u002Fbilingual or advanced fluency in English.\n* Access to a computer\u002Fmobile device for survey completion.\n* Symptoms-led diagnosis: Participants must report that they experience recurrent UTI episodes or symptoms. They must report the minimum of 2 UTIs in 6 months or 3 in 12 months, in line with the rUTI diagnostic criteria (European Association of Urology, 2020).\n\nInclusion for RUTISS- 65:\n\n* Participants must be 65 years and older\n* Access to a computer\u002Fmobile device for survey completion, paper copy available upon request.\n* All participants must have native\u002Fbilingual or advanced fluency in English.\n* Symptoms-led diagnosis: Participants must report that they experience recurrent UTI episodes or symptoms. They must report the minimum of 2 UTIs in 6 months or 3 in 12 months, in line with the rUTI diagnostic criteria (European Association of Urology, 2020).\n\nExclusion criteria (for RUTISS-Diary and RUTISS-65)\n\n* Participants must not report a current diagnosis of interstitial cystitis (measured in demographics questionnaire).\n* Symptoms of cognitive confusion or dementia.\n* No active malignancy e.g. bladder or prostate cancer\n* Participants must not report beginner or intermediate level fluency in English. Future work will be done to translate the PROMs into alternative languages.\n* In addition to the interstitial cystitis exclusion question, participants will also be asked in the demographic questionnaire if they are pregnant or have an indwelling catheter or use intermittent self-catheterisation. Participants who report \"yes\" to either of these will be excluded from participation.",{"count":55,"type":22},200,"OBSERVATIONAL","Existing patient-reported outcome measures assess acute urinary tract infection but do not support daily symptom tracking in recurrent UTI (rUTI) or meet the needs of older adults. This single-site study will develop and validate two adapted measures: the RUTISS-Diary for daily symptom monitoring and the RUTISS-65 for reporting symptoms in adults aged 65 years and over. Approximately 200 participants with rUTI will complete the RUTISS-Diary daily for 7 days and again on day 14. Participants aged 65 years and over will also complete the RUTISS-65 on days 1 and 2 to assess its reliability and validity.",[28,59,60,61],"Urological Diseases","Patient Satisfaction","Pain, Chronic",[63,64,65,66,67,68,69,70],"recurrent urinary tract infection","rUTI","outcome measure","PROMs","urinary","UTI","burden","assessment tools","NOT_YET_RECRUITING","2026-07-06",{"date":38,"type":39},{"date":75,"type":22},"2026-07-08",{"date":77,"type":22},"2027-12-24",{"name":79,"class":45},"Katherine Finlay",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100641901","preoperative-outreach-to-improve-surgical-attendance-100641901","NCT07644819","Preoperative Outreach to Improve Surgical Attendance","Reducing No-Shows in High-Risk Urology Patients Through Enhanced Preoperative Outreach","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Identified as high risk for no-show by the study predictive model\n* Scheduled to undergo a urologic procedure at UCSF\u002FUCSF affiliated sites\n\nExclusion Criteria:\n\n* Younger than 18 years of age\n* Not scheduled for a urologic procedure",{"count":88,"type":22},68,[25],"This study aims to evaluate the impact of reminder call intervention on no-shows for urologic procedures in patients identified to be high risk for no-showing. Patients scheduled to undergo a urologic procedure will be randomized into two groups: the intervention group, who receives a series of reminder calls and text messages about appointment details and patient questions prior to the procedure date; and the control group, who receives standard care only. Secondary outcomes include rates of patient re-scheduling and healthcare utilization.",[28],"2026-06-08",{"date":94,"type":39},"2026-06-12",{"date":96,"type":22},"2026-06",{"date":98,"type":22},"2026-12",{"name":100,"class":45},"University of California, San Francisco",1,{"id":103,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":26,"conditions":106,"keywords":107,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":112,"leadSponsor":113,"locationsCount":46},"100613497",{"count":21,"type":22},[25],[28,29],[31,32,33,34],"2026-04-30",{"date":110,"type":39},"2026-05-04",{"date":41,"type":39},{"date":108,"type":22},{"name":44,"class":45},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":121,"maxAge":4,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":124,"briefSummary":125,"conditions":126,"keywords":133,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100625621","ambulatory-long-length-urodynamics-evaluation-100625621","NCT07425015","Ambulatory Long Length URodynamics Evaluation","ALLURE","Inclusion Criteria:\n\n1. Male or female patient must be ≥ 22 years of age.\n2. Patient is a candidate for UDS per standard of care.\n3. Patient is able to provide informed consent.\n\nExclusion Criteria:\n\n1. Patient has one or more symptoms indicative of a urinary tract infection (UTI) (i.e., fever, costovertebral angle pain or tenderness, suprapubic tenderness, worsening urinary frequency, worsening urgency, and\u002For dysuria).\n2. Patient has a history of recurrent UTIs (≥ 3 episodes in previous 12 months).\n3. Patient has used antibiotics within the past 7 days from the baseline\u002Fscreening visit.\n4. Patient diagnosed with neurogenic LUTD (i.e., one or more of these conditions: normal-pressure hydrocephalus, cerebral palsy, spinal cord injuries, traumatic brain injury, stroke, Parkinson's disease, multiple sclerosis, meningomyelocele, spina bifida, dementia, Guillain-Barre syndrome, and tumors involving the central nervous systems or spine).\n5. Patient diagnosed with interstitial cystitis (IC), bladder pain syndrome, painful bladder syndrome or any etiology of chronic pelvic pain syndrome (CPPS).\n6. Patient with a urostomy.\n7. Patient with a colostomy.\n8. Patient has an atypical anatomic structural variation or has had a previous surgical intervention that has permanently changed structural anatomy anywhere along their lower urinary tract (urethra, pelvic floor, urethral sphincter, and\u002For bladder wall) that the principal investigator deems might compromise the placement or retention of the Glean sensors during the study (e.g., strictures).\n9. Patient has a Pelvic Organ Prolapse Quantification (POP-Q) of Grade III or higher (i.e., most distal portion of the prolapse protrudes more than 1 centimeter below the hymen).\n10. Patient with any abnormal or concerning rectal conditions such as ongoing anal fissures, rectocele, fistula, active herpes, or active yeast infections.\n11. Patient has a known inability to void.\n12. Patient has a previous history of radiation leading to bleeding (e.g., hemorrhagic radiation cystitis).\n13. Patient is pregnant (as confirmed by urine pregnancy test or medical history) or breastfeeding, pregnant within the past 6 months, or intending to become pregnant during the study period.\n14. Patients who may not be able to independently use a smart device.\n15. Subjects who, at the principal investigator's determination, would not be appropriate for this study.","22 Years",{"count":123,"type":22},101,[25],"A prospective, open-label, single arm interventional trial evaluating the safety and performance of the in-clinic and extended monitoring of the lower urinary tract using the Glean Urodynamics System.",[28,127,128,129,130,131,132],"Urinary Bladder, Overactive","Benign Prostatic Hyperplasia","Urodynamics","Home Monitoring","Urinary Incontinence (UI)","Lower Urinary Tract Dysfunction",[134,135,136],"Bright Uro","Glean Urodynamics System","Uroflowmetry","2026-04-13",{"date":139,"type":39},"2026-04-15",{"date":141,"type":39},"2026-02-17",{"date":143,"type":22},"2027-06",{"name":134,"class":145},"INDUSTRY",7,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":154,"minAge":155,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":159,"conditions":160,"keywords":163,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":101},"100627897","a-prospective-clinical-trial-evaluating-prostest-a-blood-based-molecular-assay-for-risk-stratification-and-biopsy-decision-support-in-men-with-suspected-prostate-cancer-100627897","NCT07454603","A Prospective Clinical Trial Evaluating PROSTest, a Blood-Based Molecular Assay, for Risk Stratification and Biopsy Decision Support in Men With Suspected Prostate Cancer","PROSTest_STRAT","Inclusion Criteria:\n\n* elevated PSA and\u002For abnormal digital rectal examination\n\nExclusion Criteria:\n\n* Previous Prostate cancer diagnosis","MALE","45 Years","80 Years",{"count":158,"type":22},1500,"This prospective observational study will enroll men referred for prostate biopsy due to elevated PSA and\u002For abnormal digital rectal examination, with or without pre-biopsy MRI. Peripheral blood will be collected prior to biopsy for PROSTest analysis. Biopsy histopathology will serve as the reference standard. PROSTest results will be analyzed blinded to pathology.",[161,28,162],"Prostate Cancer","Prostate Cancer (Diagnosis)",[164,165,166],"BIOPSY","MRI","PROSTATE CANCER","2026-03-02",{"date":169,"type":39},"2026-03-06",{"date":171,"type":22},"2026-03-15",{"date":173,"type":22},"2027-06-01",{"name":175,"class":145},"Wren Laboratories LLC",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":183,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":186,"briefSummary":187,"conditions":188,"keywords":195,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":209,"leadSponsor":211,"locationsCount":46},"100561028","enhanced-vitals-monitoring-after-major-surgery-trial-100561028","NCT06584825","Enhanced Vitals Monitoring After Major Surgery Trial","The Impact of Enhanced Postoperative Vitals Monitoring In-hospital and at Home vs. Standard Care After Inpatient Abdominal and Vascular Surgery: A Pilot Two-centre Randomized Controlled Study","Inclusion Criteria:\n\n1. Undergoing inpatient major abdominal (general surgery, urology, or gynecology) or vascular surgery at St. Paul's Hospital (SPH) and Mount Saint Joseph (MSJ) Hospital\n2. Length of stay of at least 48 hours (planned by the clinical team, or by the Canadian Institute of Health Information Discharge Abstract Database Expected Length of Stay (ELOS) for the surgical case mix group\n3. Self-reported fluency in reading and speaking in English for patient or home caregiver\n4. Living within British Columbia, Canada and in an area that is covered by Bell cellular network (the Cloud DX Inc. device has cellular Long Term Evolution (LTE) using the Bell network).\n\nExclusion Criteria:\n\n1. Patient refusal\n2. Transplant surgery, since these patients have a unique set of considerations and postoperative course.\n3. Inability to communicate with research personnel, perform self-monitoring of vital signs, or complete study surveys due to cognitive, language, visual, or hearing barriers\n4. Lack of capacity to consent to the study (including under the active influence of sedative medication or having received general anesthetic within the past 24 hours)\n5. Unable to use (or does not have a caregiver who can help put on\u002Ftake off) study monitoring device at home\n6. Preoperatively known planned discharge to a nursing home or rehabilitation facility\n7. Patient with known allergic reactions to any part material of the device\n8. Unable to monitor blood pressure accurately noninvasively using arm blood pressure cuffs, such as due to underlying vascular anatomy or non-pulsatile blood flow physiology\n9. Unlikely to be able to return the home monitoring kit (no fixed address, living too far away from site, etc.)","19 Years",{"count":185,"type":22},110,[25],"The aim of this clinical trial is to examine the feasibility of an enhanced vital sign monitoring solution in-hospital and at-home. This study includes adult patients undergoing inpatient major vascular or abdominal surgery. Researchers will compare the enhanced vitals monitoring group to the standard of care group to see if it may change post-operative management and outcomes. The primary question it aims to answer is if enhanced monitoring of surgical patient vitals can increase the number of days at home alive in the first 30 days after surgery. Participants in the intervention group will test two vitals monitoring devices, one in the hospital and one at home. They will also be asked to complete several questionnaires and a follow up phone call.",[189,190,191,192,193,28,194],"Surgery","Post Operative Complications","Quality of Recovery","General Surgery","Vascular Surgery","Gynecology",[196,197,198,199,200,201,202,203,204],"Days alive and at home","DAH30","Quality of Recovery 15","Pilot Randomized Controlled Trial","vitals","blood pressure","heart rate","oxygen saturation","device","2025-11-17",{"date":207,"type":39},"2025-11-21",{"date":205,"type":39},{"date":210,"type":22},"2027-12-31",{"name":212,"class":45},"University of British Columbia",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":23,"phases":223,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":101},"100604762","phase-4-the-clinical-research-of-traditional-chinese-medicine-compound-formulas-100604762","NCT07153731","The Clinical Research of Traditional Chinese Medicine Compound Formulas","Observation on the Clinical Efficacy of Shenkangling in the Treatment of Renal Ischemia-reperfusion Injury (Kidney Deficiency and Blood Stasis Syndrome)","Inclusion Criteria:\n\n1. Fulfillment of western medical diagnostic criteria requiring renal ischemia-reperfusion surgical operation and renal artery clamping time ≤ 30 min\n2. Meets the criteria for Chinese medicine identification\n3. 18 ≤ age ≤ 65\n4. Voluntary participation with signed informed consent\n\nExclusion Criteria:\n\n1. Patients with stage 4 or 5 renal insufficiency or patients with acute renal failure\n2. Those with secondary factors such as systemic lupus erythematosus, drug-induced renal damage, etc. confirmed by examination\n3. Does not meet the diagnosis of renal ischemia-reperfusion injury\n4. Cases not within the scope of action of the drug\n5. Those who have been taking other related therapeutic drugs for a long period of time, e.g., taking Chinese medicines such as Jingui Shenqi Pills by mouth for a long period of time, or those who are unable to stop taking the medicines immediately.\n6. Advanced deformity, disability, loss of labor force\n7. Combined heart, brain, liver, hematopoietic system, endocrine system and other serious primary diseases and psychiatric patients\n8. Pregnant or lactating women\n9. Critically ill patients\n10. Other circumstances deemed inappropriate for inclusion in the study","65 Years",{"count":222,"type":22},100,[224],"PHASE4","To observe the efficacy and safety of Shenkangling, a traditional Chinese medicine decoction, for renal ischemia-reperfusion injury, and to provide evidence-based medical evidence and ideas for clinical therapeutic use.",[227,28],"Urologic Injuries",[229,230,231],"Traditional Chinese Medicine","Renal Fibrosis","Renal Ischemia-reperfusion Injury","2025-09-03",{"date":234,"type":39},"2025-09-04",{"date":236,"type":22},"2025-10-01",{"date":238,"type":22},"2027-07-01",{"name":240,"class":45},"The Fourth Affiliated Hospital of Zhejiang University School of Medicine",{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":16,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":252,"conditions":253,"keywords":254,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":4},"100604595","phase-2-efficacy-and-safety-of-two-bladder-preserving-treatment-durations-with-disitamab-vedotin-plus-toripalimab-combination-in-her2-expressing-muscle-invasive-bladder-cancer-a-phase-ii-open-label-randomized-clinical-trial-100604595","NCT07151560","Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial","Disitamab Vedotin Plus Toripalimab for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial","Inclusion Criteria:\n\n1. Voluntary agreement to participate in the study and provision of signed and dated informed consent form.\n2. Male or female, aged ≥ 18 years.\n3. Life expectancy of ≥ 18 months.\n4. Pathologically and radiologically confirmed diagnosis of muscle-invasive bladder cancer (MIBC), clinical stage cT2-4aN0M0.\n5. Ability to provide tumor tissue specimen from the primary site for HER2 testing; HER2 expression of IHC 1+, 2+, or 3+.\n6. No prior systemic therapy for bladder cancer.\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n8. Adequate cardiac, bone marrow, hepatic, and renal function (as per the reference ranges of the investigating center).\n\nExclusion Criteria:\n\n1. History of malignancies other than urothelial carcinoma, with the following exceptions:Patients who have received potentially curative therapy and have no evidence of the disease for 5 years.Adequately treated basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the cervix, or other in situ carcinomas that have undergone curative resection.\n2. Conditions affecting drug absorption, distribution, metabolism, or excretion.\n3. Prior allogeneic stem cell or solid organ transplantation.Prior systemic anti-cancer therapy (including Chinese herbal medications with anti-cancer indications).Less than 4 weeks between the completion of prior therapy and the first dose of study treatment, or presence of persistent adverse events from previous treatments that have not recovered to ≤ Grade 1 per CTCAE (excluding alopecia or pigmentation).\n4. History or current presence of congenital or acquired immunodeficiency diseases.\n5. Active or documented history of autoimmune or inflammatory disorders.",{"count":249,"type":22},60,[251],"PHASE2","This study aims to evaluate the efficacy of disitamab vedotin combined with toripalimab as a bladder-preserving treatment combination in patients with HER2 positive locally advanced MIBC, including one year bladder-intact DFS (BI-DFS) and safety.",[28],[255,256],"Bladder-preserving","Disitamab Vedotin","2025-08-25",{"date":232,"type":39},{"date":260,"type":22},"2025-08-30",{"date":262,"type":22},"2030-08-30",{"name":264,"class":45},"Renmin Hospital of Wuhan University"]